Patients
Infertile women who attended the Assisted Reproduction Unit, The University of Hong Kong-Queen Mary Hospital for IVF treatment were recruited for this study.
They had regular menstrual cycles, normal uterus and no significant intrauterine or ovarian abnormalities as determined by transvaginal ultrasonography. Only women 105 with regular menstrual cycles and male factor infertility who had not received any steroidal hormones for 2 months or more prior to the study and also agreed to the use of condoms for contraception during the study cycle were recruited for endometrial biopsies in the natural cycle (Liu et al., 2010) . The study protocol was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority 110
Hong Kong West Cluster. Written informed consent was obtained from all patients prior to participation in the study.
Endometrial biopsies were taken from patients undergoing diagnostic laparoscopy for assessment of tubal patency from 2004 to 2005. These samples were taken in different phases of the menstrual cycle including early-/mid-proliferate 115 phase (Day 1-9, EPMP, n=8), late proliferate phase (Day 10-14, LP, n=8), early secretory phase ES, n=8) , middle secretory phase MS, n=15) , and late secretory phase LS, n=6) . The donors of these samples in different groups did not differ significantly (p>0.05) in terms of age and duration of infertility. 120
Human endometrial samples from the stimulated cycle were collected from early 2002 to December 2008. The ovarian stimulation was carried out as described previously using the long protocol (Ng et al., 2000) . Endometrial biopsies in the stimulated cycles (n=32) were obtained seven days after the hCG injection (hCG+7), and endometrial biopsies in natural cycles (n=15) were taken on day LH+7 (7 days6 after luteinizing hormone surge) as described previously (Liu et al., 2008) . Those patients were recruited when embryo transfer was not performed due to the failure of fertilization caused by male factors, absence of spermatozoa in testicular sperm extraction on the day of oocyte retrieval or when the serum E 2 level was >20,000pmol/L on the day of hCG injection. 130
Tissue Collection
Biopsies were performed as an outpatient procedure from the fundal and upper part of the body of the uterus using the Pipelle device (CCD Laboratories, France).
The biopsy specimen was snap-frozen in liquid nitrogen and was stored at -80º C until 135 total RNA isolation was achieved. Serum E 2 and progesterone (P 4 ) levels were also measured on the day of the biopsy by commercially available chemiluminescent-based immunoassay kits as reported previously (Ng et al., 2000) .
RNA extraction, reverse transcription and real-time PCR 140
Total RNAs from human endometrial biopsies were extracted using the Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. RNA samples (300 ng) were reverse-transcribed into cDNA using TaqMan® Reverse Transcription Reagents (PE Applied Biosystems, Foster City, CA). Multiplex real-time polymerase chain reaction using 18S as an 145 internal control for the normalization of RNA loading was performed in a 20 μl reaction mixture with Assays-on-Demand Gene Expression Assay for human Olfm-1, -2, -3 and -4 (PE Applied Biosystems). Samples from the mid-secretory phase were used as calibrators for different PCR experiments.
The human Olfm-1 (Hs00255159_m1), Olfm-2 (Hs00608880_m1), Olfm-3 (Hs00379238_m1), Olfm-4 150 (Hs00197437_m1), estrogen receptor-α (Hs00174860_m1), estrogen receptor-β (Hs00230957_m1) and ribosomal 18S (Hs99999901_s1) TaqMan probes were used (PE Applied Biosystems).
Protein extraction and Western blotting 155
Total proteins from endometrial biopsies and cell lysates [Ishikawa, JAr and fallopian tube epithelial OE-E6/E7 (Lee et al., 2001 ) cells] were dissolved in RIPA solution (1X PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors. The Olfm-1, β-catenin, E-cadherin protein expression was analyzed by Western blotting. The membranes were probed with affinity 160 purified rabbit anti-human Olfm polyclonal antibody (1:1000 dilution, Zymed Lab, hours. After thorough washing, the membrane was visualized by enhanced 170 chemiluminescence reagent (Santa Cruz). To normalize the protein loading, the membranes were stripped and detected for β-actin using anti-β-actin antibody (Sigma, St Louis, MO).
Production, purification and labeling of human recombinant Olfm (rhOlfm) 175
The full length Olfm-1 coding sequence was amplified from cDNA reverse transcribed from total RNA isolated from human endometrial epithelial cells by PCR using the Expand Long Template PCR system with proof reading Taq DNA polymerase (Roche, Mannheim, Germany) and gene-specific primers (Forward: C. rhOlfm-1 was purified using a protein refolding kit (Novagen, Gibbstown, NJ) as described previously (Lee et al., 2006) . The identity of the purified protein was Labeling kit (Molecular Probes, Invitrogen, Carlsbad, CA) using the protocol described by the manufacturer. Then, the cells were incubated with the medium containing the labeled recombinant protein (5 µg/ml) for 3 hrs and washed twice with PBS, and the signal was detected under a florescence microscope.
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Immunohistochemistry
Human endometrial biopsies were fixed in buffered formalin, embedded in paraffin, sectioned at 5 μm in thickness, and mounted on poly-lysine coated-slides.
Tissue sections were de-paraffinized, which was followed by antigen retrieval using the Target Retrieval Solution (DakoCytomation, Carpinteria, CA) as previously 200 described (Lee et al., 2006) . A rabbit anti-human Olfm polyclonal antibody (1:200), no primary antibody or an antibody pre-absorbed with the antigen/blocking peptide (Zymed Lab) was included.
Finally, positive signal was detected using 3,3'-diaminobenzidine (DakoCytomation). Nuclei were counter-stained with hematoxylin. The sections were observed with a Zeiss Axioskop microscope 205 (Photometrics Sensys, Roper Scientific, Tuesoa, AZ) with bright-field optics.
Spheroids-endometrial cell attachment assay
Human choriocarcinoma cells (JAr, ATCC HTB-144) and endometrial adenocarcinoma cells (Ishikawa, ECACC 99040201) were cultured at 37 o C in a 210 humid atmosphere with 5% CO 2 . Adhesion of choriocarcinoma JAr cells to endometrial Ishikawa cells was quantified using an adhesion assay as described (Hohn et al., 2000; Uchida et al., 2007; Liu et al., 2010) with modifications. For the co-culture study, JAr cells were treated with 0.1-10 µg/ml Olfm-1, 5 µM methotrexate (MTX) as a positive control and 1 µg/ml BSA as a negative control for 48 hrs. were counted under a dissecting microscope, and expressed as the percentage of the total number of spheroids used (% adhesion). Photographs of the cultures were taken with a Nikon Eclipse TE300 inverted microscope (Nikon, Tokyo, Japan).
Statistical analysis 230
All the data were analyzed by statistical software (SigmaPlot 10.0 and SigmaStat 2.03; Jandel Scientific, San Rafael, CA). The non-parametric analysis of variance on rank test for multiple comparisons followed by the Mann-Whitney U test was used when the data were not normally distributed. A probability value <0.05 was considered to be statistically significant. 235
Results
Expression of Olfms in human endometrium in the menstrual cycle
Olfm has four known transcripts (Olfm-1, -2, -3 and -4) and their expressions in different phases of the menstrual cycle were studied by real-time PCR. Olfm-1 and 240 -2 transcripts were highly expressed in the proliferative phase, but not at the secretory phase of the menstrual cycle. Significant differences (p<0.05, >3-fold) in the expression levels of these transcripts were found between the proliferative phases and the mid-/late-secretory phases (Fig. 1A ). Yet, no significant difference (p>0.05) was found in the expression of Olfm-3 or -4 transcripts in samples from different phases of 245 the cycle (Fig. 1A) .
The polyclonal antibody against Olfm-1 peptide was designed and raised from the rabbit. Western blotting confirmed a specific band of the expected size (50-kDa) in the human endometrial lysate (Fig. 1B) . Olfm-1 antibody could not be neutralized by Olfm-2 and -3 peptides. The expression of Olfm-1 protein was higher in the 250 proliferative phase of the menstrual cycle (Fig. 1C) . Immunohistochemistry on a paraffin-embedded human endometrial section identified strong Olfm-1 immunoreactivity in the luminal and glandular epithelium, and a weaker signal in the stromal cells (Fig. 1D) . The signal could be nullified when the antibody was pre-absorbed with Olfm-1 peptide. 255
Effect of ovarian stimulation on endometrial Olfm transcripts expression
The expression of Olfm transcripts in human endometria isolated from patients who underwent ovarian stimulation was compared with that from the patients from natural cycles. Both Olfm-1 and -2 transcripts were found to be significantly 260 (p<0.05) down-regulated in the stimulated group (Fig. 2) . Although there was a slight increase in the expression of Olfm-4 transcript in the stimulated group, the difference was not statistically significant. and estrogen receptor α and β transcript levels (Fig. 3) . Serum E 2 levels on hCG/LH day and P 4 levels on hCG/LH+7 day were negatively correlated (p<0.05) with Olfm-2, 270
Association of
but not Olfm-1 transcript levels. Interestingly, estrogen receptor α was positively correlated (p<0.001) with both Olfm-1 and Olfm-2 levels. Yet, estrogen receptor β was negatively correlated (p<0.01) with Olfm-2 but not Olfm-1 levels in the human endometrial samples.
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Effect of Olfm-1 on Spheroids-endometrial cell attachment assay rhOlfm-1 protein was expressed in E. coli as inclusion bodies. Soluble rhOlfm-1 was obtained from the inclusion bodies after dialysis. The binding of AlaxaFlour-labeled Olfm-1 was tested on JAr and Ishikawa cells. It was found that both JAr and Ishikawa bound AlaxaFlour-labeled rhOlfm-1 (Fig. 4A) . To study how 280 rhOlfm-1 modulates the attachment process in vitro, we used the spheroids-endometrial cells co-culture assay to study the attachment of spheroids onto Ishikawa cells. Treatment of JAr cells for 48 hrs with rhOlfm-1 (0.1-10 µg/ml) did not affect the attachment rate onto Ishikawa cells (Fig. 4B) . However, there was a significant decrease (p<0.05) in the attachment rate when 10 µg/ml rhOlfm-1 was 285 used to treat the Ishikawa cells (Fig. 4C) . When both JAr and Ishikawa cells were treated with rhOlfm-1 (0.1-10 µg/ml), there was a dose-dependent suppression of JAr spheroids attachment onto the Ishikawa cells ( Figure 4D ). The percentage of attachment decreased from 87% to 57% from 0.1 to 10 µg/ml Olfm-1 used.
Similarly, the positive control MTX (5 µM) strongly suppressed the attachment of JAr 290 onto the Ishikawa cells in all the experiments performed. No significant decrease in attachment was observed when 1µg/ml BSA was used (97% vs 95%) when compared with the untreated control. The average viability of the JAr and Ishikawa cells in all the groups after treatment was 90-94% as determined by Trypan Blue staining (data not shown). 295
Effect of Olfm on E-cadherin and β-catenin expression in JAr and Ishikawa cells
To study whether Olfm regulates Wnt-signaling and extracellular matrix molecule expression in JAr and Ishikawa cells during the attachment process, the expression levels of β-catenin and E-cadherin were determined. Treatment of the 300
JAr or Ishikawa cells with Olfm-1 at 0-10µg/ml for 24 hrs and 28 hrs, respectively, did not affect E-cadherin and β-catenin expression (Fig. 5) . No observable change in
Discussion
Previous microarray analysis suggested that down-regulation of Olfm-1 was found in the receptive endometrium (Horcajadas et al., 2004) . Our findings further suggested that both endometrial Olfm-1 and -2 transcripts, as well as Olfm-1 protein were down-regulated in the mid-secretory phase of the natural cycle and in patients 310 who received ovarian stimulation for IVF treatment. Moreover, recombinant human Olfm-1 protein binds to JAr and Ishikawa cells, and suppresses spheroid-endometrial cell attachment in vitro.
The suppressive effect was not associated with down-regulation of β-catenin or E-cadherin expression in neither Ishikawa nor JAr
cells. 315
Both Olfm-1 and -2 transcripts were down-regulated in the secretory phase of the menstrual cycle when the serum estrogen and progesterone levels were high.
Estrogen promotes, while progesterone suppresses the expression of ER and PR in the endometrial cells during the late proliferative phase and secretory phase of the menstrual cycle (Nisolle et al., 1994) . Since the expression of Olfm-1 and -2 320 transcripts were positively correlated with the endometrial ERα level and high serum progesterone level suppresses ERα expression, it is possible that the steroid hormones may play both direct and indirect roles in regulating Olfm expression in vitro and in vivo. Yet, no consensus estrogen responsive element (ERE) or the progesterone responsive element (PRE) were found in the Olfm proximal promoter regions, 325
suggesting that the steroid regulation of Olfm-1 and -2 expression may be indirect.
Accumulating evidence suggested that high serum estradiol level advances endometrial development (Basir et al., 2001 ) not conducive to embryo implantation.
Results from our laboratory demonstrated an advancement of gene expression profiles in patient with ovarian hyperstimulation (Liu et al., 2008) . However, Olfm 330 transcripts remained at similar levels at the secretory phase of the natural cycle, suggesting that down-regulation of Olfm expression by ovarian stimulation may not be associated with an advancement of endometrial development.
Fluorescent-labeled Olfm-1 strongly binds to JAr and Ishikawa cells. It is possible that Olfm-1 may form a protective layer on the apical surface of the luminal 335 epithelium, and its down-regulation in the peri-implantation period allows apposition and adhesion of the blastocysts onto the receptive endometrium while allowing the other molecules also to expose and interact with the embryo. Yet, further investigations are needed to study if Olfm-1 binds to a specific receptor onto these cell lines and whether these bindings are specific to cells in reproductive tract. 340
A similar function has been proposed for MUC-1, a potent anti-adhesive extracellular matrix molecule in the endometrium (Meseguer et al., 1998) . MUC-1 is down-regulated at the implantation site during the receptive period (Carson et al., 1998) . Results form the JAr spheroids-Ishikawa cells attachment assay support our hypothesis that rhOlfm-1 may play a similar role to MUC-1 in embryo attachment. 345
Interestingly, treatment of the JAr trophoblast cells with Olfm-1 had no effect on attachment, but treatment of the Ishikawa cells with Olfm-1 at a high concentration (10 µg/ml) significantly reduced the attachment rate, albeit that the Ishikawa cells express a detectable amount of Olfm protein (data not shown). Importantly, when both JAr and Ishikawa cells were treated with Olfm-1, the change in the attachment 350 rate became more prominent, showing a dose-dependent inhibition on attachment (from 97% to 57%).
Yet, results from this study suggested that further decrease in Olfm-1 expression in the hyperstimulated endometrium is not associated with an increase in endometrial receptivity in vivo. In fact, the expression of Olfm-1 transcript in the 355 secretory phrase of natural cycle is low. It is likely that down-regulation of other implantation-related (e.g. Wnt-signaling) signaling molecules may affect embryo attachment in vivo. For example, high level of DKK-1, a Wnt-signaling inhibitor which was commonly found in the endometria of ovarian stimulated patients, inhibits spheroids attachment in vitro (Liu et al., 2010) . Similarly, inactivation of nuclear 360
Wnt-β-catenin signaling limits blastocyst competency for implantation (Xie et al., 2008; Chen et al., 2009) .
A differential expression of cadherins and intergrins may be involved in the successful attachment of an embryo onto the human endometrium (van der Linden et al., 1995) . A recent study demonstrated that an increased E-cadherin expression is 365 associated with an increase in receptivity in non-receptive endometrial (AN3-CA) cells to BeWo spheroids attachment (Rahnama et al., 2009 ). However, we did not observe detectable changes in β-catenin and E-cadherin expression in Ishikawa or JAr cells, although rhOlfm-1 binds to both cell types. Therefore, it is likely that either Olfm-1 functions as a physical barrier for implantation or another unidentified 370 signaling pathway may play an important role in the implantation process. The results were pooled from at least 4 independent experiments using more than 
